Previous investigations have provided evidence that sorafenib possesses the capability to induce the onset of ferroptosis in the treatment of liver cancer [6, 7], thus providing the possibility of confirming the inverse regulatory relationship between PLAG1 and ferroptosis. Here, PLAG1 is linked to liver cancer.